Use Nektar Therapeutics story together with your assets to protect against small markets fluctuations as well as to check it against diversification policy that fits your risk preferences.
This story from stocks.us.reuters.com contributed to next trading day price increase. The story delta to the next closing price was 1.09% . The story delta to the current price is 4.49% .
Sacramento Bee - Apr 10, 2012
By Nektar Therapeutics SAN FRANCISCO, April 10, 2012 -- /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will host an Investor and Analyst R&D Day for its institutional investors and research analysts on Monday, April 16, 2012 from 12:00 pm to 5:00 ...
pharmabiz.com - Apr 4, 2012
Nektar Therapeutics, a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms, has dosed first subject in a phase I clinical study to evaluate the pharmacokinetics and ...
Nektar Doses First Subjects in Phase 1 Clinical Study Evaluating NKTR-192, a ... - PR Newswire (press release)
RTT News - Mar 28, 2012
(RTTNews) - Nektar Therapeutics (NKTR: News ) reported that its partner Affymax, Inc. announced that the US Food and Drug Administration, or FDA, has approved OMONTYS (peginesatide) injection for the treatment of anemia due to chronic kidney disease in ...
Nektar Therapeutics - NKTR - FDA Approval of OMONTYS - Fyxnews
Affymax, Takeda Win Approval of Anemia Drug to Challenge Amgen - Xconomy
Shares Owned by Insiders show percentage of outstanding shares owned by insiders (such as key officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
USA 
Equity Search
Advanced Search
Market Screener
Adviser Directory
Suggest Portfolio
Backtest Watchlist
Analyze Correlations
View Transactions
Check Volatility
Import Equities
Summary
Fundamentals
Technicals
Performance
Valuation
Volatility
History
News
Management
Discussion
